PITTSBURGH, Oct. 14, 2025 (GLOBE NEWSWIRE) -- Krystal Biotech, Inc. (KRYS) (the “Company”) (NASDAQ: KRYS) announced today that the United States Food and Drug Administration (FDA) granted platform ...
Demand for adeno-associated viral (AAV) vectors is increasing as more and more cell and gene therapy firms use them to make products. In response, vector suppliers are embracing faster, more efficient ...
Findings from a phase I trial (NCT04183166) evaluating TG4050, a neoantigen therapeutic vaccine, in patients with operable, human papillomavirus (HPV)–negative head and neck squamous cell carcinoma ...
Dispatch Biotherapeutics Inc. is taking aim at solid tumors with a new viral vector/antigen technology backed by major industry names such as Arch Venture Partners and Bristol Myers Squibb Co. With ...
The "Viral Vector Collaboration and Licensing Deals 2016-2025" has been added to ResearchAndMarkets.com's offering.This report contains a comprehensive listing of 413 viral vector deals announced ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results